Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls

Bibliography

• Giacca M, Zacchigna S. Virus-mediated gene delivery for human gene therapy. J Control Release 2012;161:377-88
   PubMed Web of Science ®Google Scholar
• Russell WC. Adenoviruses: update on structure and function. J Gen Virol 2009;90:1-20
   PubMed Web of Science ®Google Scholar
• Martin CS. Latest insights on adenovirus structure and assembly. Viruses 2012;4:847-77
   PubMed Web of Science ®Google Scholar
• Bradley RR, Lynch DM, Iampietro MJ, et al. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J Virol 2012;86:625-9
   PubMed Web of Science ®Google Scholar
• Frahm N, deCamp AC, Friedrich DP, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 2012;122:359-67
   PubMed Web of Science ®Google Scholar
• Edelstein M. Gene therapy clinical trials worldwide - Online library by Journal of Gene Medicine. John Wiley and Sons Ltd; 2014. http://www.wiley.com/legacy/wileychi/genmed/clinical/
   Google Scholar
• Khare R, Chen CY, Weaver EA, Barry MA. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 2011;11:241-58
   PubMed Web of Science ®Google Scholar
• Small JC, Ertl HC. Viruses - from pathogens to vaccine carriers. Curr Opin Virol 2011;1:241-5
   Web of Science ®Google Scholar
• Zaiss AK, Machado HB, Herschman HR. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 2009;108:778-90
   PubMed Web of Science ®Google Scholar
• Lanuti M, Gao GP, Force SD, et al. Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum Gene Ther 1999;10:463-75
   PubMed Web of Science ®Google Scholar
• Dormond E, Perrier M, Kamen A. From the first to the third generation adenoviral vector: what parameters are governing the production yield? Biotechnol Adv 2009;27:133-44
   PubMed Web of Science ®Google Scholar
• Vetrini F, Ng P. Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses 2010;2:1886-917
   PubMed Web of Science ®Google Scholar
• Cao H, Yang T, Li XF, et al. Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression. Gene Ther 2011;18:173-81
   PubMed Web of Science ®Google Scholar
• Ahn M, Gamble A, Witting SR, et al. Vector and helper genome rearrangements occur during production of helper-dependent adenoviral vectors. Hum Gene Ther Methods 2013;24:1-10
   Google Scholar
• Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007;28:42-58
   PubMed Web of Science ®Google Scholar
• Jia H, Kling J. China offers alternative gateway for experimental drugs. Nat Biotechnol 2006;24:117-18
   PubMed Web of Science ®Google Scholar
• Toth K, Wold WS. Increasing the efficacy of oncolytic adenovirus vectors. Viruses 2010;2:1844-66
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Obrist F, et al. Trial Watch:: oncolytic viruses for cancer therapy. Oncoimmunology 2014;3:e28694
   PubMed Web of Science ®Google Scholar
• Hemminki A. Oncolytic immunotherapy: where are we clinically? Scientifica (Cairo) 2014;2014:862925
   PubMedGoogle Scholar
• Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010;70:4297-309
   PubMed Web of Science ®Google Scholar
• Pesonen S, Diaconu I, Kangasniemi L, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res 2012;72:1621-31
   PubMed Web of Science ®Google Scholar
• Pesonen S, Diaconu I, Cerullo V, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 2012;130:1937-47
   PubMed Web of Science ®Google Scholar
• Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010;18:1874-84
   PubMed Web of Science ®Google Scholar
• Hemminki O, Diaconu I, Cerullo V, et al. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther 2012;20:1821-30
   Google Scholar
• Liikanen I, Ahtiainen L, Hirvinen ML, et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther 2013;21:1212-23
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health. Registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Available from: http://www.clinicaltrials.gov/ [Accessed 19 August 2014]
   Google Scholar
• Middleton PG, Alton EW. Gene therapy for cystic fibrosis: which postman, which box? Thorax 1998;53:197-9
   PubMed Web of Science ®Google Scholar
• Perricone MA, Morris JE, Pavelka K, et al. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. Hum Gene Ther 2001;12:1383-94
   PubMed Web of Science ®Google Scholar
• Rosenecker J, Harms KH, Bertele RM, et al. Adenovirus infection in cystic fibrosis patients: implications for the use of adenoviral vectors for gene transfer. Infection 1996;24:5-8
   PubMed Web of Science ®Google Scholar
• Yla-Herttuala S. Cardiovascular gene therapy with vascular endothelial growth factors. Gene 2013;525:217-19
   PubMed Web of Science ®Google Scholar
• Lahteenvuo JE, Lahteenvuo MT, Kivela A, et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. Circulation 2009;119:845-56
   PubMed Web of Science ®Google Scholar
• Priddy FH, Brown D, Kublin J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008;46:1769-81
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-93
   PubMed Web of Science ®Google Scholar
• Peters W, Brandl JR, Lindbloom JD, et al. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans. Vaccine 2013;31:1752-8
   PubMed Web of Science ®Google Scholar
• Asmuth DM, Brown EL, DiNubile MJ, et al. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J Infect Dis 2010;201:132-41
   PubMed Web of Science ®Google Scholar
• Tamminga C, Sedegah M, Regis D, et al. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 2011;6:e25868
   PubMed Web of Science ®Google Scholar
• Peiperl L, Morgan C, Moodie Z, et al. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS One 2010;5:e13579
   Google Scholar
• Gurwith M, Lock M, Taylor EM, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013;13:238-50
   PubMed Web of Science ®Google Scholar
• Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012;4:115ra1
   PubMed Web of Science ®Google Scholar
• Abel B, Tameris M, Mansoor N, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 2010;181:1407-17
   PubMed Web of Science ®Google Scholar
• Hoft DF, Blazevic A, Stanley J, et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 2012;30:2098-108
   PubMed Web of Science ®Google Scholar
• O’Hara GA, Duncan CJ, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012;205:772-81
   PubMed Web of Science ®Google Scholar
• Ogwang C, Afolabi M, Kimani D, et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One 2013;8:e57726
   PubMed Web of Science ®Google Scholar
• Sheehy SH, Duncan CJ, Elias SC, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 2012;20:2355-68
   PubMed Web of Science ®Google Scholar
• Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80:148-58
   PubMed Web of Science ®Google Scholar
• Xu Z, Tian J, Smith JS, Byrnes AP. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol 2008;82:11705-13
   PubMed Web of Science ®Google Scholar
• Carlisle RC, Di Y, Cerny AM, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 2009;113:1909-18
   PubMed Web of Science ®Google Scholar
• Othman M, Labelle A, Mazzetti I, et al. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 2007;109:2832-9
   PubMed Web of Science ®Google Scholar
• Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010;28:950-7
   PubMed Web of Science ®Google Scholar
• Appaiahgari MB, Pandey RM, Vrati S. Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines. Clin Vaccine Immunol 2007;14:1053-5
   PubMed Web of Science ®Google Scholar
• Barouch DH, Kik SV, Weverling GJ, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011;29:5203-9
   PubMed Web of Science ®Google Scholar
• Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010;5:357-61
   PubMed Web of Science ®Google Scholar
• Benlahrech A, Harris J, Meiser A, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 2009;106:19940-5
   PubMed Web of Science ®Google Scholar
• Majhen D, Calderon H, Chandra N, et al. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum Gene Ther 2014;25:301-17
   PubMed Web of Science ®Google Scholar
• Parker AL, Waddington SN, Nicol CG, et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 2006;108:2554-61
   PubMed Web of Science ®Google Scholar
• Xu Z, Qiu Q, Tian J, et al. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med 2013;19:452-7
   PubMed Web of Science ®Google Scholar
• Zhang Y, Bergelson JM. Adenovirus receptors. J Virol 2005;79:12125-31
   PubMed Web of Science ®Google Scholar
• Bradshaw AC, Parker AL, Duffy MR, et al. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathog 2010;6:e1001142
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2010;18:243-50
   PubMed Web of Science ®Google Scholar
• Kimball KJ, Preuss MA, Barnes MN, et al. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 2010;16:5277-87
   PubMedGoogle Scholar
• Liikanen I, Monsurro V, Ahtiainen L, et al. Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. Mol Ther 2011;19:1858-66
   Google Scholar
• Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 2005;11:66-79
   PubMed Web of Science ®Google Scholar
• Wortmann A, Vohringer S, Engler T, et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther 2008;16:154-62
   PubMed Web of Science ®Google Scholar
• Weaver EA, Nehete PN, Buchl SS, et al. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One 2009;4:e5059
   PubMed Web of Science ®Google Scholar
• Appaiahgari MB, Saini M, Rauthan M, et al. Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect 2006;8:92-104
   PubMed Web of Science ®Google Scholar
• Lambe T, Carey JB, Li Y, et al. Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. Sci Rep 2013;3:1443
   Google Scholar
• Coughlan L, Alba R, Parker AL, et al. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2010;2:2290-355
   PubMed Web of Science ®Google Scholar
• Doronin K, Shashkova EV, May SM, et al. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther 2009;20:975-88
   PubMed Web of Science ®Google Scholar
• Di Paolo NC, van Rooijen N, Shayakhmetov DM. Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver. Mol Ther 2009;17:675-84
   PubMed Web of Science ®Google Scholar
• Kuhlmann KF, Van Geer MA, Bakker CT, et al. Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma. Cancer Gene Ther 2009;16:585-97
   PubMed Web of Science ®Google Scholar
• Behr M, Kaufmann JK, Ketzer P, et al. Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds. PLoS One 2014;9:e95723
   Google Scholar
• Short JJ, Rivera AA, Wu H, et al. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy. Mol Cancer Ther 2010;9:2536-44
   PubMed Web of Science ®Google Scholar
• Zhang Z, Krimmel J, Zhang Z, et al. Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model. Hum Gene Ther 2011;22:1137-42
   PubMed Web of Science ®Google Scholar
• Campos SK, Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 2007;7:189-204
   PubMed Web of Science ®Google Scholar
• MacLeod SH, Elgadi MM, Bossi G, et al. HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice. Cancer Gene Ther 2012;19:888-98
   PubMed Web of Science ®Google Scholar
• Matsui H, Sakurai F, Katayama K, et al. A targeted adenovirus vector displaying a human fibronectin type III domain-based monobody in a fiber protein. Biomaterials 2013;34:4191-201
   PubMed Web of Science ®Google Scholar
• Vellinga J, Van der HS, Hoeben RC. The adenovirus capsid: major progress in minor proteins. J Gen Virol 2005;86:1581-8
   PubMed Web of Science ®Google Scholar
• Meulenbroek RA, Sargent KL, Lunde J, et al. Use of adenovirus protein IX (pIX) to display large polypeptides on the virion – generation of fluorescent virus through the incorporation of pIX-GFP. Mol Ther 2004;9:617-24
   PubMed Web of Science ®Google Scholar
• Gorman JJ, Wallis TP, Whelan DA, et al. LH3, a “homologue” of the mastadenoviral E1B 55-kDa protein is a structural protein of atadenoviruses. Virology 2005;342:159-66
   PubMed Web of Science ®Google Scholar
• Harris JD, Roberts ML, Perumal D, et al. Efficient liver-directed gene transfer by in situ generation of retroviral vector from adenoviral templates. In Vivo 2009;23:885-93
   PubMed Web of Science ®Google Scholar
• Sitaraman V, Hearing P, Ward CB, et al. Computationally designed adeno-associated virus (AAV) Rep 78 is efficiently maintained within an adenovirus vector. Proc Natl Acad Sci USA 2011;108:14294-9
   PubMed Web of Science ®Google Scholar
• Huang S, Kamihira M. Development of hybrid viral vectors for gene therapy. Biotechnol Adv 2013;31:208-23
   PubMed Web of Science ®Google Scholar
• Murphy SJ, Chong H, Bell S, et al. Novel integrating adenoviral/retroviral hybrid vector for gene therapy. Hum Gene Ther 2002;13:745-60
   PubMed Web of Science ®Google Scholar
• Zheng C, Cotrim AP, Nikolov N, et al. A novel hybrid adenoretroviral vector with more extensive E3 deletion extends transgene expression in submandibular glands. Hum Gene Ther Methods 2012;23:169-81
   Google Scholar
• Henckaerts E, Linden RM. Adeno-associated virus: a key to the human genome? Future Virol 2010;5:555-74
   PubMed Web of Science ®Google Scholar
• Hausl MA, Zhang W, Muther N, et al. Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B. Mol Ther 2010;18:1896-906
   PubMed Web of Science ®Google Scholar
• Chalberg TW, Portlock JL, Olivares EC, et al. Integration specificity of phage phiC31 integrase in the human genome. J Mol Biol 2006;357:28-48
   PubMed Web of Science ®Google Scholar
• Ramachandran M, Yu D, Wanders A, et al. An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors. Mol Ther 2013;21:2008-18
   PubMed Web of Science ®Google Scholar
• Wold WS, Toth K. Chapter three – Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. Adv Cancer Res 2012;115:69-92
   PubMed Web of Science ®Google Scholar
• Woller N, Gurlevik E, Ureche CI, et al. Oncolytic viruses as anticancer vaccines. Front Oncol 2014;4:188
   PubMedGoogle Scholar
• Bressy C, Benihoud K. Association of oncolytic adenoviruses with chemotherapies: an overview and future directions. Biochem Pharmacol 2014;90:97-106
   PubMed Web of Science ®Google Scholar
• Medina-Kauwe LK. Development of adenovirus capsid proteins for targeted therapeutic delivery. Ther Deliv 2013;4:267-77
   PubMedGoogle Scholar
• Galinier R, Gout E, Lortat-Jacob H, et al. Adenovirus protein involved in virus internalization recruits ubiquitin-protein ligases. Biochemistry 2002;41:14299-305
   PubMed Web of Science ®Google Scholar
• Agadjanian H, Ma J, Rentsendorj A, et al. Tumor detection and elimination by a targeted gallium corrole. Proc Natl Acad Sci USA 2009;106:6105-10
   PubMed Web of Science ®Google Scholar
• Hwang JY, Lubow J, Chu D, et al. A mechanistic study of tumor-targeted corrole toxicity. Mol Pharm 2011;8:2233-43
   PubMed Web of Science ®Google Scholar
• Hwang JY, Lubow DJ, Chu D, et al. Photoexcitation of tumor-targeted corroles induces singlet oxygen-mediated augmentation of cytotoxicity. J Control Release 2012;163:368-73
   PubMed Web of Science ®Google Scholar
• Hwang JY, Lubow DJ, Sims JD, et al. Investigating photoexcitation-induced mitochondrial damage by chemotherapeutic corroles using multimode optical imaging. J Biomed Opt 2012;17:015003
   Google Scholar
• Li J, Liu H, Li L, et al. The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma. Oncol Rep 2013;29:895-902
   PubMed Web of Science ®Google Scholar